Recombinant factor VIII Fc for the treatment of haemophilia A

Prophylaxis with factor VIII (FVIII) is the current therapeutic approach for people with haemophilia A. However, standard half‐life (SHL) FVIII products must be injected frequently, imposing a substantial burden on the individual and making it difficult to tailor therapy according to patient need an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermans, Cedric, Mancuso, Maria Elisa, Nolan, Beatrice, Pasi, K. John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252769/
https://www.ncbi.nlm.nih.gov/pubmed/33650192
http://dx.doi.org/10.1111/ejh.13610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252769/
https://www.ncbi.nlm.nih.gov/pubmed/33650192
http://dx.doi.org/10.1111/ejh.13610

Ejemplares similares